Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab in Advanced Gynecologic Tumors (Observational)
ChiCTR2100049393Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Henan University of Science and Technology
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in Cervical Cancer (CC), endometrial cancer (EC), ovarian cancer and 1 more, sponsored by First Affiliated Hospital of Henan University of Science and Technology. Primary endpoint: overall survival. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
Cervical Cancer (CC)endometrial cancer (EC)ovarian cancergynecological cancer
Beyond the preview
Go deeper on ChiCTR2100049393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049393.